Publicação
Levodopa response in later stages of Parkinson's disease: a case-control study
| Resumo: | Levodopa (l-dopa) remains the gold-standard of Parkinson's disease (PD) treatment. With disease progression, l-dopa efficacy on PD cardinal motor symptoms may decrease. Nevertheless, l-dopa has a safer profile compared to other antiparkinsonian drugs, especially in elderly and frail patients. Indeed, a simplification of drug regimen in later disease stages may be beneficial. We have recently reported a smaller l-dopa responsiveness of motor and non-motor symptoms (NMS), in a population of late-stage (LS) PD patients compared indirectly with an unmatched advanced (AD) PD group previously submitted to deep brain stimulation (DBS). |
|---|---|
| Autores principais: | Fabbri, Margherita |
| Outros Autores: | Coelho, Miguel; Abreu, Daisy; Ferreira, Joaquim J |
| Assunto: | Dementia Late stage Levodopa Parkinson's disease |
| Ano: | 2020 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | acesso restrito |
| Instituição associada: | Universidade de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório da Universidade de Lisboa |
| Resumo: | Levodopa (l-dopa) remains the gold-standard of Parkinson's disease (PD) treatment. With disease progression, l-dopa efficacy on PD cardinal motor symptoms may decrease. Nevertheless, l-dopa has a safer profile compared to other antiparkinsonian drugs, especially in elderly and frail patients. Indeed, a simplification of drug regimen in later disease stages may be beneficial. We have recently reported a smaller l-dopa responsiveness of motor and non-motor symptoms (NMS), in a population of late-stage (LS) PD patients compared indirectly with an unmatched advanced (AD) PD group previously submitted to deep brain stimulation (DBS). |
|---|